Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifabutin + polymyxin B + cefiderocol
- Development stage
- Unknown
- Lead developer
- BioVersys
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination antibiotic regimen is being developed by BioVersys AG for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). The regimen consists of BV100 (an intravenous formulation of the RNA polymerase inhibitor rifabutin), the polymyxin antibiotic polymyxin B, and the siderophore cephalosporin cefiderocol. This triple-combination approach is designed to overcome multi-drug resistance mechanisms in Gram-negative bacteria. BV100 specifically targets the bacterial RNA polymerase, while polymyxin B disrupts the outer membrane and cefiderocol inhibits cell wall synthesis by utilizing the bacteria's own iron transport systems to enter the periplasmic space. The combination is currently being evaluated in Phase 2b clinical trials (RIV-CARE) for hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and bloodstream infections.
- Other names
- BV100 with polymyxin B plus cefiderocolBV-100 with polymyxin B plus cefiderocolBV 100 with polymyxin B plus cefiderocol
02
Targets
PBP (Penicillin-binding protein family)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on rifabutin + polymyxin B + cefiderocol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifabutin + polymyxin B + cefiderocol.